📰 Package Leaflet News
Page 5 - Package Leaflet News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Package Leaflet. Real-time updates on events, politics, business and more.
July 26, 2022
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
July 26, 2022
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
July 26, 2022
Nuvaxovid is the first protein-based COVID-19 vaccine approved for use in adolescents in Japan GAITHERSBURG, Md., July 26, 2022 /PRNewswire/ --Novavax,Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine received expanded manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for primary immunization...
May 20, 2022
GlaxoSmithKline UK Ltd have informed the MHRA that an incorrect version of the Summary of Product Characteristics section 4.2 and the Patient Information Leaflet is inside the sealed pack, and contains unapproved text.
April 21, 2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination Vaccine (CIC). The CIC combines Novavax' COVID-19 vaccine ...
April 20, 2022
Phase 1/2 clinical trial of COVID-19-Influenza combination vaccine candidate indicates vaccine is well-tolerated and immunogenicData from this combination trial will inform planned Phase 2 dose
April 20, 2022
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
April 19, 2022
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
April 19, 2022
Nuvaxovid is the first protein-based COVID-19 vaccine approved for use in adults aged 18 and older in JapanApproval is first in the world for NVX-CoV2373 that includes both primary and booster
April 13, 2022
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...